Methylene blue is not a peptide. It is a synthetic phenothiazine dye first made in 1876, and it sits in this catalogue because the same research suppliers who list peptides increasingly stock it as a mitochondrial research reagent. This profile covers what the compound actually does in cells, what the animal and human imaging literature supports, where the evidence stops, and what the 16 suppliers on Peptides.SO are charging for it.
> Research use only. Methylene blue on this site is sold as a laboratory reagent for in-vitro and preclinical investigation. Nothing here is a protocol for human or animal administration. The pharmaceutical form (methylene blue injection) is a prescription drug with its own labelling; research-grade solutions are not that product.
What methylene blue is
Chemically, methylene blue is methylthioninium chloride, a tricyclic phenothiazine with a delocalised positive charge. It is water-soluble, deeply blue in its oxidised form, and colourless when reduced to leucomethylene blue. Its biology follows from that reversible redox couple: the molecule can accept electrons from NADH-dependent flavoenzymes and hand them to cytochrome c, cycling between the two states without being consumed.
Its clinical history is long. It was the first synthetic drug used against malaria, it is the standard antidote for acquired methemoglobinemia, and it is used off-label for vasoplegia after cardiac surgery. The review From Mitochondrial Function to Neuroprotection – an Emerging Role for Methylene Blue (PMID 28840449) summarises that background and explains why interest shifted from the dye's antidote uses to its behaviour inside mitochondria.
Mechanism: an alternative electron carrier
Rerouting electrons around complexes I and III
The mitochondrial electron transport chain normally passes electrons from NADH through complex I, ubiquinone, complex III and cytochrome c to complex IV (cytochrome c oxidase), which reduces oxygen to water. When complex I or III is damaged, electrons leak and form superoxide. Methylene blue can take electrons directly from NADH (via flavin-dependent enzymes) and deliver them to cytochrome c, bypassing the damaged segment. The same review (PMID 28840449) describes this as rerouting electrons "directly from NADH to cytochrome c, increasing the activity of complex IV".
The cellular consequences were quantified in the 2008 FASEB Journal study Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways (PMID 17928358). In human IMR90 fibroblasts, nanomolar methylene blue increased complex IV activity by about 30%, raised cellular oxygen consumption by 37–70%, increased heme synthesis, and extended replicative lifespan by more than 20 population doublings. The authors also showed that the compound induced phase-2 antioxidant enzymes in HepG2 cells and reversed premature senescence caused by hydrogen peroxide or cadmium.
Cytochrome c oxidase induction
Beyond the acute electron-shuttling effect, repeated exposure appears to up-regulate cytochrome c oxidase itself. The J. Alzheimer's Disease review Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase (PMID 20463399) frames Alzheimer pathology as energy hypometabolism driven by amyloid-beta toxicity and argues that a compound which raises heme synthesis and complex IV activity addresses that deficit directly. This is a hypothesis paper backed by cell data, not a clinical result.
Hormesis: why concentration matters
Methylene blue's dose-response is biphasic. At low concentrations it acts as an electron carrier and reduces reactive oxygen species; at high concentrations it competes with oxygen for electrons, generates superoxide, and can inhibit the very enzymes it enhances at low doses. The rat study Methylene blue improves brain oxidative metabolism and memory retention in rats (PMID 14724055) showed the pattern directly: brain homogenates showed increased cytochrome c oxidation "with the low but not the high MB concentrations tested". For in-vitro work this means concentration series are mandatory; a single high concentration will generate a pro-oxidant artefact and be misread as toxicity.
Monoamine oxidase inhibition
Methylene blue is a potent, reversible inhibitor of monoamine oxidase A. This is the source of its most serious drug interaction: combined with serotonergic drugs it can precipitate serotonin toxicity. The review CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity (PMID 20142303) found that 13 of 14 reported cases of methylene blue CNS toxicity met the Hunter criteria for serotonin toxicity, and attributed the mechanism to the MAO-inhibitory property interacting with reuptake inhibitors. For research design, any experiment that pairs methylene blue with serotonergic compounds needs to account for this.
Guanylate cyclase and nitric oxide signalling
The vasoplegia use rests on a different mechanism. Methylene blue inhibits soluble guanylate cyclase, the enzyme that converts nitric oxide signalling into cGMP-mediated vasodilation. The Texas Heart Institute Journal paper Methylene Blue Is a Guanylate Cyclase Inhibitor That Does Not Interfere with Nitric Oxide Synthesis (PMID 27047301) locates the effect downstream of NO production, at the cyclase, not at nitric oxide synthase. Older summaries that describe methylene blue as a "NOS inhibitor" are imprecise.
Tau aggregation
Methylene blue and its reduced derivative hydromethylthionine (LMTM) inhibit tau aggregation in vitro, which is the basis of a long clinical programme in Alzheimer's disease. The results have been complicated. Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease (PMID 31658058) reports that two phase III trials found no difference between high doses and a low dose intended as a control, and that a subsequent pharmacokinetic analysis of 1,162 patients showed a steep concentration-response relationship at the low end of the exposure range. The design rationale for the follow-up trial is described in Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate (PMID 36281683). The tau programme is a pharmaceutical development story about a derivative, not evidence about research-grade methylene blue solutions.
What the preclinical memory literature shows
The rodent memory work from the Gonzalez-Lima group is the most cited part of the methylene blue literature. Three papers carry most of the weight.
- •Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats (PMID 12384216): rats given sodium azide, a cytochrome oxidase inhibitor, lost spatial memory retention in a holeboard maze. Post-training methylene blue restored it. This is a rescue experiment in a metabolically impaired model.
- •Methylene blue improves brain oxidative metabolism and memory retention in rats (PMID 14724055): in normal rats, low-dose post-training methylene blue improved probe-trial retention (66% versus 31% for saline) and raised brain cytochrome c oxidation 24 hours after administration but not at one or two hours, which the authors read as enzyme induction rather than an acute effect.
- •The brain metabolic enhancer methylene blue improves discrimination learning in rats (PMID 17428524): the same group extended the finding from single-session tasks to a multi-day spatial discrimination task.
These are consistent, well-controlled studies from one laboratory, all in rats, all using post-training administration during the memory consolidation window. They do not establish anything about chronic use, about other species, or about baseline-healthy cognition outside the consolidation window.
Human imaging studies
Two randomised, double-blind, placebo-controlled fMRI studies from the same group at UT Health San Antonio are the only controlled human cognitive data.
Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain (PMID 27351678) enrolled 26 healthy adults aged 22–62. One hour after a single low oral dose, methylene blue increased fMRI response in the bilateral insular cortex during a psychomotor vigilance task and in prefrontal, parietal and occipital cortex during a short-term memory task, and was associated with a 7% increase in correct responses at memory retrieval.
Methylene blue modulates functional connectivity in the human brain (PMID 26961091) used task-based and resting-state fMRI in the same design and found reduced cerebral blood flow in a task-related network during a visuomotor task alongside stronger resting-state connectivity in regions linking perception and memory.
Both studies were single-dose, acute, and small. The authors describe them as support for "further investigations in healthy and disease populations".
Antimicrobial photodynamic research
A separate literature uses methylene blue as a photosensitiser: when illuminated at around 660 nm it generates singlet oxygen that kills bacteria, fungi and some viruses. The systematic review Methylene blue mediated antimicrobial photodynamic therapy in clinical human studies: The state of the art (PMID 32473398) screened 1,260 articles and analysed 85 human clinical studies outside dentistry. This is a mature clinical application in periodontology and wound care, and it depends on light activation; the dye alone in the dark has no comparable antimicrobial effect at those concentrations.
Research specifications
| Property | Value |
|---|---|
| Chemical name | Methylthioninium chloride (3,7-bis(dimethylamino)phenothiazin-5-ium chloride) |
| Formula | C16H18ClN3S |
| Molecular weight | 319.85 g/mol (anhydrous); commercial material is usually the trihydrate |
| Class | Phenothiazine dye; redox cycler; MAO-A inhibitor; soluble guanylate cyclase inhibitor |
| Solubility | Freely soluble in water; soluble in ethanol |
| Common research formats | 1% (10 mg/mL) aqueous solution in 30–60 mL dropper bottles; USP-grade powder |
| Storage | Room temperature, protected from light; solutions darken and precipitate with age |
| Analytical check | UV-Vis absorbance maximum at 664 nm; HPLC for azure impurities (azure A, B, C) |
Pharmaceutical-grade methylene blue is specified to limit azure impurities and heavy metals. Industrial dye-grade material can contain both. For any cell-based work the grade matters more than the price, and a supplier certificate of analysis should show the impurity profile, not just the assay percentage.
Methylene blue on Peptides.SO: what suppliers are charging
The platform tracks 18 methylene blue listings from 16 suppliers, checked against supplier storefronts through 25 September 2026. The median list price is $54.99, with a range of $15.99 to $139. Six suppliers carry a branded "NeuroPro Plus" methylene blue product (median $59.50, $16.99–$124.99); the remainder are plain 1% solutions in 30–60 mL bottles.
Two things to note when comparing. First, the listings are not size-matched: a $16 30 mL bottle and a $90 30 mL bottle of the same nominal concentration differ in grade or brand, not quantity, so price-per-millilitre alone does not separate them. Second, methylene blue is a thinly covered product here compared with the peptides in the same catalogues (BPC-157 is listed by about 100 suppliers; methylene blue by 16), so a single supplier's pricing moves the median.
- •Current offers: methylene blue listings
- •Vetting a supplier's certificate: supplier checklist and COA interpretation guide
- •Reagent handling: peptide storage best practices (the light-sensitivity section applies)
Related research compounds
Methylene blue is usually studied alongside other mitochondrial and NAD-pathway agents rather than peptides. Readers looking at the metabolic side of the literature may find the 5-Amino-1MQ NNMT inhibitor profile and the Epithalon vs Pinealon vs NAD+ comparison useful context; on the neuroprotection side, the P21 CNTF-derived peptide profile covers a peptide approach to the same questions.
Frequently asked questions
Is methylene blue a peptide?
No. It is a small synthetic phenothiazine molecule (MW ~320). It appears on peptide supplier sites because the same customer base buys it as a research reagent.
Why does the concentration matter so much?
Because the dose-response is biphasic. At low concentrations methylene blue carries electrons and lowers oxidative stress; at high concentrations it generates superoxide and inhibits mitochondrial enzymes. The rat study cited above (PMID 14724055) saw the enhancement only at the low concentrations tested.
Is there human evidence for cognitive effects?
Two small randomised fMRI studies in healthy adults (PMID 27351678, PMID 26961091) found acute changes in task-related brain activity and a modest improvement in memory retrieval after a single dose. There are no controlled trials of chronic use for cognition in healthy people.
What about the Alzheimer's trials?
Those trials used hydromethylthionine (LMTM), a stabilised reduced derivative developed by TauRx, not research-grade methylene blue. The phase III results were mixed and the interpretation rests on post-hoc concentration-response analysis (PMID 31658058).
Why is there a serotonin warning?
Methylene blue inhibits monoamine oxidase A. Combined with serotonin reuptake inhibitors it has caused serotonin toxicity (PMID 20142303). This matters for experimental design as well as for clinical use.
Why does research-grade methylene blue turn skin, urine and glassware blue?
The oxidised form is an intense dye and stains most surfaces. Research solutions should be handled with the same precautions as any histological stain.
---
This article is for educational and research purposes only. Methylene blue sold through the suppliers listed on Peptides.SO is a laboratory reagent and is not intended for human or animal use. It is not a substitute for the prescription drug, and nothing here should be read as medical advice.